Quanterix Co. (NASDAQ:QTRX) Director David R. Walt Purchases 131,869 Shares

Quanterix Co. (NASDAQ:QTRX) Director David R. Walt acquired 131,869 shares of the stock in a transaction dated Friday, June 6th. The stock was bought at an average price of $5.43 per share, for a total transaction of $716,048.67. Following the purchase, the director now owns 1,628,802 shares of the company’s stock, valued at $8,844,394.86. The trade was a 8.81% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Quanterix Price Performance

Quanterix stock opened at $6.58 on Wednesday. The company has a market capitalization of $255.49 million, a PE ratio of -6.21 and a beta of 1.05. Quanterix Co. has a one year low of $4.05 and a one year high of $19.18. The business has a 50 day simple moving average of $5.29 and a 200 day simple moving average of $7.86.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Monday, May 12th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.16. The business had revenue of $30.33 million during the quarter, compared to the consensus estimate of $28.27 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. Equities analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Quanterix

Several institutional investors have recently bought and sold shares of the business. Jane Street Group LLC raised its position in Quanterix by 4.2% in the 1st quarter. Jane Street Group LLC now owns 58,313 shares of the company’s stock valued at $380,000 after purchasing an additional 2,366 shares during the last quarter. SCS Capital Management LLC bought a new position in Quanterix in the 1st quarter valued at $2,307,000. Goldman Sachs Group Inc. raised its position in Quanterix by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 349,696 shares of the company’s stock valued at $2,277,000 after purchasing an additional 59,655 shares during the last quarter. Invenomic Capital Management LP bought a new position in Quanterix in the 1st quarter valued at $5,872,000. Finally, AQR Capital Management LLC raised its position in Quanterix by 204.4% in the 1st quarter. AQR Capital Management LLC now owns 98,990 shares of the company’s stock valued at $644,000 after purchasing an additional 66,470 shares during the last quarter. Institutional investors own 86.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on QTRX. Canaccord Genuity Group lowered their price objective on shares of Quanterix from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Scotiabank reissued an “outperform” rating on shares of Quanterix in a report on Tuesday, March 25th. Wall Street Zen lowered Quanterix from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Leerink Partnrs lowered Quanterix from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 30th. Finally, Leerink Partners reissued a “market perform” rating and set a $8.00 price objective (down previously from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Quanterix currently has an average rating of “Hold” and a consensus target price of $15.60.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.